PARIS--(BUSINESS WIRE)--Regulatory News:
ABIVAX (Paris:ABVX) (Euronext Paris: FR0012333284 – ABVX), a biotechnology company harnessing the immune system to develop a functional cure for HIV and treatments for inflammatory/autoimmune diseases and cancer, today announces that its senior management team will participate in upcoming events for investors and business development professionals.
March 12-14, 2018: BIO-Europe Spring in Amsterdam
Prof. Hartmut Ehrlich, M.D., CEO ABIVAX, will give a corporate update presentation on ABIVAX on Tuesday, March 13 at 11:00 in room E105
- March 16, 2018: Full Year 2017 Financial Results
- March 19-20, 2018: BIO Asia International Conference in Tokyo
- April 8-10, 2018: H.C. Wainwright Global Life Sciences Conference in Monaco
About ABIVAX (www.abivax.com/en)
ABIVAX is mobilizing the body’s natural immune machinery to treat patients with viral infections, autoimmune diseases and cancer. A clinical-stage company, ABIVAX leverages its antiviral and immune enhancing platforms to optimize candidates to cure HIV and treat inflammatory bowel diseases and liver cancer. ABIVAX is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo : ABVX). More information on the company is available at www.abivax.com.
Follow us on Twitter @ABIVAX_